POSTERS

All posters will be displayed throughout the meeting
All posters will also be presented as 60-second snap posters
See programme for timings of snap poster presentations

P1
The effect of bisphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-schore bone marker approach in the TRIO study
Fatma Gossiel
Department of Oncology and Metabolism, University of Sheffield, UK

P2
Comparison of treatment resonder rates for three oral bisphosphonates: The TRIO Study
Margaret Paggiosi
Department of Oncology and Metabolism, University of Sheffield, UK

P3
Long-term safety of zoledronic acid treatment for osteoporosis in men and women: A systematic review and meta-analysis of clinical trials
Rajneet Singh
National University of Ireland, Galway, Ireland

P4
Bisphosphonate binding to hudroxyapatite: Differing affinities and local delivery for bone regeneration
Zhidao Xia
Centre for Nanohealth, College of Medicine, Swansea University, UK

P5
Impact of renal function on BMD response to bisphosphonate treatment: Real world observational data using linkage to national registers
Bo Abrahamsen
University of Southern Denmark

P6
Audit to assess FRAX risk assessment and subsequent management accordingt to the NICE and NOGG guidelines in a primary care practice in Smethwick, Birmingham
Niam Arora
University of Birmingham, UK

P7
Defining how oestrogen influences the anti-tumour effects of adjuvant bisphosphonates using in vivo models of breast cancer
Victor Canuas-Landero
Department of Oncology and Metabolism, University of Sheffield, UK

P8
Understanding atypical femur fractures
Angela Cheung
Department of Medicine, University of Toronto, Canada

P9
Bone-bound bisphosphonates inhibit proliferation of breast cancer cells
Jillian Cornish
Department of Medicine, University of Auckland, New Zealand

P10
Patterns of recurrence in breast cancer on bisphosphonates and control arm: analyses of the AZURE (BIG 01/04) study
Stella D'Oronzo
University of Sheffield/University of Bari Aldo Moro, Bari, Italy

P11
Clinical characteristics and effects of bisphosphonates in a Hungarian cohort of patients with Paget's disease of bone
Judit Donàth
NI of Rheumatology & Physiotherapy, Budapest, Hungary

P12
The differential effect of zoledronic acid and oestrogen on the immune response to cancer
Christopher George
Department of Oncology and Metabolism, University of Sheffield, UK

P13
DKK1 - A novel biomarker for predicting risk of breast cancer metastasis to the lung
Ana Lopez-Guajardo
Department of Oncology and Metabolism, University of Sheffield, UK

P14
Effect of bisphosphonates on tooth development in patients with osteogeneisis imperfecta
Barbro Malmgren
Department of Dental Medicine, Karolinska Institutet, Sweden

P15
Characterising a mouse model for atypical fracture
Samuel Monzem
Comparative Biomedical Sciences, Royal Veterinary College, London, UK

P16
DOCK4 - A novel biomarker for predicting risk of breast cancer bone metastasis
Maria Oliva
Department of Oncology and Metabolism, University of Sheffield, UK

P17
The ZOLMENO study - exploring the effects of ZOLedronic Acid and MENOpausal status in patients with early breast cancer
Elisavet Theodoulou
Department of Oncology and Metabolism, University of Sheffield, UK

P18
Cyclin-dependent kinaes (CDKs) as drug targets within breast cancer bone metastasis
Steven Wood
Department of Oncology and Metabolism, University of Sheffield, UK

P19
Bisphosphonates and denosumab reduce all-cause mortality risk after hip fracture
Martina Behanova
Ludwig Boltzmann Institute for Osteology, Hanusch Hospital of the WGKK and AUVA Trauma Center, 1st Medical Dept of Hanusch Hospital, Vienna, Austria

P20
The effect of zoledronate on lifespan and healthspan
Zhengqi Chen
Department of Oncology and Metabolism, University of Sheffield, UK

P21
Bone targeted fluoroquinolone antibiotic conjugatte bisphosphonates for the treatment of osteomyelitis biofilms
Frank Ebetino
BioVinc, USA

P22
Bisphosphonates regulate autophagy in vitroand in vivo
James Edwards
Nuffield Dept of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, UK

P23
Genetically-achieved disturbances to the expression levels of TNFSF11 receptors sway the effects of zoledronic acid on growing mouse skeletons
Frédéric Lézot
University of Nantes, France

P24
TLR9 regulates inflammatory effects of bisphosphonates
Katri Selander
Department of Oncology, University Hospital of Oulu, Finland

P25
Competitive equilibrium-based bisphosphonate displacement ot enhance extraction socket healing in a model of early stage bisphosphonate-related osteonecrosis of the jaw (BRONJ)
Shuting Sun
BioVinc, USA

P26
Bisphosphonate based imaging probes: new tools for bone imaging and disease diagnosis
Shuting Sun
BioVinc, USA

P27
Bisphosphonate use in the horse
Larry Suva
Veterinary Physiology & Pharmacology, Texas A&M University, USA

P28
The experience of pamidronate treatment in 43 children with osteogenesis imperfecta
Mikhail Kostik
Department of Hospital Pediatrics, St Petersburg State Pediatric Medical University, Russia

P29
Pamidronate provides the highest remission rate in the chronic non-bacterial osteomyelitis, compared to antirheumatic drugs and tumor necrosis factor-a inhibitors
Mikhail Kostik
Department of Hospital Pediatrics, St Petersburg State Pediatric Medical University, Russia

P30
A paradoxical acute hypercalcaemia following a bisphosphonate infusion - a case report
Lauren Passby
Sheffield Teaching Hospitals NHS Trust/University of Sheffield, UK

P31
Healing of myeloma bone disease with bone anabolic therapy – are bisphosphonates really necessary?
Alanna Green
Department of Oncology and Metabolism, University of Sheffield, UK

P32
Novel niclosamide-bisphosphonate vectors as bone-targeted therapy for multiple myeloma
Jennifer Down
Department of Oncology and Metabolism, University of Sheffield, UK

P33
The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2 alpha]pyridin-3-yl)ethyl-bisphosphonate), with reduced bone affinity, which is as effective as zoledronate in the treatment of myeloma bone disease in JJN3-NOD/SCID-γ mice
Shelly Lawson
Department of Oncology and Metabolism, University of Sheffield, UK

P34
Scientific discoveries and technological developments with bisphosphonates (BPs) in Argentina, 1972-2019
Javier Castorina
Gador S.A., Argentina

P35
Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis
Mickael Hiligsmann
Maastricht University, Netherlands

P36
Genome-wide screens reveal molecular determinants of nitrogen-containing bisphosphonates' action
Lauren Surface
Endocrine Unit, Massachusetts General Hospital, USA

P37
Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models
Andy Chantry
Department of Oncology and Metabolism, University of Sheffield, UK

P38
Innovative approaches to creation of bifunctional hydroxybisphosphonic molecules for specific drug deliver to the bone
Maxim Egorov
ATLANTHERA, France

P39
HBP-bound doxorubicin 12b80: a promising new therapy for bone cancer
Sèbastien Cagnol
ATLANTHERA, France

P40
Upper gastrointestinal safety with the buffered solution of Alendronate 70 mg: 6 years of post-marketing experience
Lorraine Zakin
EffRx Pharmaceuticals SA, Switzerland

P41
Novel bone-targeting bisphosphonate-chemotherapeutic conjugates: from clinical proof-of-concept to second generation compounds
Shawn Zinnen
MBC Pharma Inc. Aurora, CO, USA

P42
Benzylideneacetone Derivatives Ameliorate Ovariectomy-induced Osteoporosis in ddY Mice Based on the Capacities to Inhibit Osteoclastogenesis and Activate Osteoblastogenesis
Gil Hong Park
Department of Biochemistry & Molecular Biology, Korea University College of Medicine, South Korea

P43
Identifying genetic risk factors for atypical femur fractures
Peter Ebeling
Department of Medicine, School of Clinical Sciences, Monash University, Australia

P44
Impact of bisphosphonate treatment on the fracture risk predicted by Raman spectroscopic analysis of fingernail
Rene Beattie
J Renwick Beattie Consulting, Ballycastle, UK

P45
Bisphosphonates prevent turnover of primary bone in fracture healing
Willy Hofstetter
Department of Biomedical Research (DBMR), University of Bern, Switzerland